ijms-logo

Journal Browser

Journal Browser

State-of-the-Art Molecular Mechanisms and Pathophysiology of Bone and Soft Tissue Diseases in Italy

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 2747

Special Issue Editor


E-Mail Website
Collection Editor
Department of Medical and Surgical Specialties and Dentistry, University of Campania “Luigi Vanvitelli”, Via De Crecchio 4, 80138 Naples, Italy
Interests: vitamin D; osteoporosis; sarcopenia; CRPS; musculoskeletal pain; neuromuscular diseases; lysosomal storage disorders
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Topical Collection of the International Journal of Molecular Sciences (IJMS) aims to efficiently publish Italian contributions to all aspects of bone and soft tissue diseases, including original studies or perspective reviews. We encourage the submission of manuscripts that provide novel and mechanistic insights and papers that report significant advances in these fields. The main topics include but are not limited to:

  • Osteoporosis;
  • Metatarsalgia;
  • Polymyalgia rheumatica;
  • Bone cancer;
  • Osteoarthritis;
  • Rheumatoid arthritis (RA);
  • Scleroderma;
  • Granulomatosis with polyangiitis (GPA);
  • Churg–Strauss syndrome;
  • Lupus;
  • Systemic lupus erythematosus (SLE);
  • Microscopic polyangiitis (MPA);
  • Polymyositis/dermatomyositis;
  • Marfan syndrome.

Prof. Dr. Giovanni Iolascon
Collection Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

13 pages, 660 KiB  
Review
The Rationale for Using Neridronate in Musculoskeletal Disorders: From Metabolic Bone Diseases to Musculoskeletal Pain
by Giovanni Iolascon and Antimo Moretti
Int. J. Mol. Sci. 2022, 23(13), 6921; https://doi.org/10.3390/ijms23136921 - 22 Jun 2022
Cited by 7 | Viewed by 2491
Abstract
Neridronate or ((6-amino-1-hydroxy-1-phosphonohexyl) phosphonic acid) is an amino-bisphosphonate (BP) synthetized in Italy in 1986. Bisphosphonates are molecules with a P-C-P bond in their structure that allows strong and selectively binding to hydroxyapatite (HAP) as well as osteoclasts inhibition through different mechanisms of action. [...] Read more.
Neridronate or ((6-amino-1-hydroxy-1-phosphonohexyl) phosphonic acid) is an amino-bisphosphonate (BP) synthetized in Italy in 1986. Bisphosphonates are molecules with a P-C-P bond in their structure that allows strong and selectively binding to hydroxyapatite (HAP) as well as osteoclasts inhibition through different mechanisms of action. Neridronate was initially used to treat Paget disease of the bone, demonstrating effectiveness in reducing bone turnover markers as well as pain. The interesting molecular properties of neridronate foster its wide use in several other conditions, such as osteogenesis imperfecta, and osteoporosis. Thanks to the unique safety and efficacy profile, neridronate has been used in secondary osteoporosis due to genetic, rheumatic, and oncological diseases, including in pediatric patients. In the last decade, this drug has also been studied in chronic musculoskeletal pain conditions, such as algodystrophy, demonstrating effectiveness in improving extraskeletal outcomes. This review highlights historical and clinical insights about the use of neridronate for metabolic bone disorders and musculoskeletal pain conditions. Full article
Show Figures

Figure 1

Back to TopTop